Cary Gross, professor of medicine and of epidemiology at Yale School of Medicine, has been working with a dataset of 35,000 non-small cell lung cancer patients, looking for signs of disparities in access to PD-1 checkpoint inhibitors.
For nearly 30 years, the American Cancer Society’s prostate cancer screening guidelines have advised men to discuss prostate-specific antigen, or PSA, testing with a clinician and weigh potential benefits and harms, rather than treat screening as an unquestioned routine. This “informed decision-making” recommendation was consistent with guidelines from all major professional organizations in the United States, Canada, and Europe.
